Implicity Raises $38M as AI Cardiac Monitoring Cuts Mortality by 26%

·
Listen to this article~4 min

Paris-based Implicity raises $38M to expand AI cardiac monitoring in the US. Its platform has shown a 26% reduction in mortality and is used at over 250 medical centers.

Implicity, a Paris-based innovator in AI-driven cardiac remote monitoring, just closed a $38 million funding round. The company plans to use the fresh capital to accelerate its expansion into the United States, advance its AI capabilities, and develop next-generation heart failure prediction algorithms. The round was led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co. ### Why This Funding Matters "I didn't become a physician to manage data – I became one to treat patients," says Dr. Arnaud Rosier, electrophysiologist, CEO and co-founder of Implicity. "This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care – and that's the future of cardiology I've been chasing since my first year as an electrophysiologist." That quote captures the heart of the problem Implicity is solving. Cardiologists today are drowning in data. Remote monitoring devices generate a constant stream of alerts, and clinicians spend too much time triaging them instead of treating patients. ### The European MedTech Funding Wave To understand Implicity's raise, it helps to look at the broader investment landscape. In 2026 alone, European startups in cardiac care, remote monitoring, and AI-enabled MedTech have pulled in roughly $228 million across various deals. - Portugal's Hope Care raised $6.5 million for remote patient monitoring. - UK-based TidalSense secured $18 million for AI respiratory diagnostics. - Swiss startup Xsensio brought in $6.5 million for continuous monitoring. - France's DentalMonitoring closed an $91 million round for AI-powered orthodontic monitoring. - Lifeaz raised $14 million for its connected defibrillator. - FineHeart announced $90 million in private capital and EU grants for advanced heart-failure tech. France, in particular, is becoming a hotbed for health tech innovation. ### How Implicity's Platform Works Founded in 2016, Implicity specializes in cardiac remote monitoring and software as a medical device. Its independent, universal platform monitors patients with cardiac implantable electronic devices (CIEDs) and heart failure. Remote patient monitoring is the standard of care in cardiology. But each new data stream adds complexity. Clinicians waste time navigating multiple systems and triaging alerts. Implicity's AI-driven platform aggregates, normalizes, and analyzes data across the full continuum of care – regardless of device manufacturer. The results speak for themselves: a 26% reduction in mortality and a 4% reduction in hospitalizations. ### Adoption on Both Sides of the Atlantic That evidence has driven adoption in the US and Europe. Implicity's platform is used daily at over 250 medical centers, representing more than 120,000 monitored patients. In France, it runs across major public hospital networks, from AP-HP to CHU Tours and CHU Grenoble. At Institut Mutualiste Montsouris, it helped scale from 250 to 5,000 patients. Nicolas Herschtel, Partner at IRIS' Growth team, added: "In the evolving HealthTech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today. We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure." ### What's Next for Implicity With this funding, Implicity is poised to deepen its US presence and continue developing AI that predicts heart failure earlier. For American healthcare systems grappling with clinician burnout and data overload, that's welcome news. The company's ability to reduce mortality while cutting hospitalizations shows the potential of AI in medicine. And as European MedTech continues to attract record investment, Implicity is one to watch.

📌 Worth Reading Next